NCT06969963View on ClinicalTrials.gov

Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

July 23, 2024

Study Completion Date

July 23, 2024

Conditions
Bioequivalence Study in Healthy Subjects
Interventions
DRUG

Lepsiramp, 0.5 Mg/mL Oral Suspension

Test product

DRUG

Fycompa, 0.5 Mg/mL Oral Suspension

Reference product

Trial Locations (1)

Unknown

Advanced Research Center (ARC), Cairo

Sponsors
All Listed Sponsors
collaborator

Advanced Research Center (ARC)

UNKNOWN

collaborator

Global Napi Pharmaceuticals for Global Advanced Pharmaceuticals

UNKNOWN

lead

Aya Mohammed Abdel Magid Abdel Hamid

OTHER

NCT06969963 - Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations | Biotech Hunter | Biotech Hunter